The Importance of the Assessment of Lutetium Lu 177 Dotatate for Advanced Midgut Neuroendocrine Tumors to the Field

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, discusses the overall impact of the research assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 American Society of Clinical Oncology Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg explained why this research assessing lutetium Lu 177 dotatate is important to the field, and how the study results could change treatment opportunities for patients with advanced midgut neuroendocrine tumors.